相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Pathogenesis of Myeloma
Kenneth C. Anderson et al.
ANNUAL REVIEW OF PATHOLOGY: MECHANISMS OF DISEASE, VOL 6 (2011)
PI3K/p110δ is a novel therapeutic target in multiple myeloma
Hiroshi Ikeda et al.
BLOOD (2010)
Targeting TORC2 in multiple myeloma with a new mTOR kinase inhibitor
Bao Hoang et al.
BLOOD (2010)
Development of target-specific treatments in multiple myeloma
Asher A. Chanan-Khan et al.
BRITISH JOURNAL OF HAEMATOLOGY (2010)
Predictive Biomarkers of Sensitivity to the Phosphatidylinositol 3′ Kinase Inhibitor GDC-0941 in Breast Cancer Preclinical Models
Carol O'Brien et al.
CLINICAL CANCER RESEARCH (2010)
Hotspot mutations of PIK3CA and AKT1 genes are absent in multiple myeloma
Said I. Ismail et al.
LEUKEMIA RESEARCH (2010)
The PI3K/Akt Pathway as a Target in the Treatment of Hematologic Malignancies
Kiyotaka Kawauchi et al.
ANTI-CANCER AGENTS IN MEDICINAL CHEMISTRY (2009)
Regulation and Importance of the PI3K/Akt/mTOR Signaling Pathway in Hematologic Malignancies
Kiyotaka Kawauchi et al.
ANTI-CANCER AGENTS IN MEDICINAL CHEMISTRY (2009)
The BH3-only protein Bim plays a critical role in leukemia cell death triggered by concomitant inhibition of the PI3K/Akt and MEK/ERK1/2 pathways
Mohamed Rahmani et al.
BLOOD (2009)
Antimyeloma Activity of the Orally Bioavailable Dual Phosphatidylinositol 3-Kinase/Mammalian Target of Rapamycin Inhibitor NVP-BEZ235
Douglas W. McMillin et al.
CANCER RESEARCH (2009)
DEPTOR Is an mTOR Inhibitor Frequently Overexpressed in Multiple Myeloma Cells and Required for Their Survival
Timothy R. Peterson et al.
CELL (2009)
The novel orally bioavailable inhibitor of phosphoinositol-3-kinase and mammalian target of rapamycin, NVP-BEZ235, inhibits growth and proliferation in multiple myeloma
Philipp Baumann et al.
EXPERIMENTAL CELL RESEARCH (2009)
Biological properties of potent inhibitors of class I phosphatidylinositide 3-kinases: from PI-103 through PI-540, PI-620 to the oral agent GDC-0941
Florence I. Raynaud et al.
MOLECULAR CANCER THERAPEUTICS (2009)
Bone marrow microenvironment and the identification of new targets for myeloma therapy
K. Podar et al.
LEUKEMIA (2009)
Treatment of Multiple Myeloma: A Comprehensive Review
Robert A. Kyle et al.
CLINICAL LYMPHOMA & MYELOMA (2009)
Combined functional and molecular analysis of tumor cell signaling defines 2 distinct myeloma subgroups:: Akt-dependent and Akt-independent multiple myeloma
Angela Zoellinger et al.
BLOOD (2008)
The identification of 2-(1H-indazol-4-yl)-6-(4-methanesulfonyl-piperazin-1-ylmethyl)-4-morpholin-4-yl-thieno[3,2-d]pyrimidine (GDC-0941) as a potent, selective, orally bioavailable inhibitor of class I PI3 kinase for the treatment of cancer
Adrian J. Folkes et al.
JOURNAL OF MEDICINAL CHEMISTRY (2008)
The p85α Subunit of Class IA Phosphatidylinositol 3-Kinase Regulates the Expression of Multiple Genes Involved in Osteoclast Maturation and Migration
Veerendra Munugalavadla et al.
MOLECULAR AND CELLULAR BIOLOGY (2008)
Sensing and Integration of Erk and PI3K Signals by Myc
Tae Lee et al.
PLOS COMPUTATIONAL BIOLOGY (2008)
The selectivity of protein kinase inhibitors: a further update
Jenny Bain et al.
BIOCHEMICAL JOURNAL (2007)
Evaluation of combination chemotherapy: Integration of nonlinear regression, curve shift, isobologram, and combination index analyses
L Zhao et al.
CLINICAL CANCER RESEARCH (2004)
Drug therapy: Multiple myeloma
RA Kyle et al.
NEW ENGLAND JOURNAL OF MEDICINE (2004)
Preferential killing of PTEN-null myelomas by PI3K inhibitors through Akt pathway
J Zhang et al.
ONCOGENE (2003)
Essential, nonredundant role for the phosphoinositide 3-kinase p110δ in signaling by the B-cell receptor complex
ST Jou et al.
MOLECULAR AND CELLULAR BIOLOGY (2002)
Malignant hematopoietic cell lines: in vitro models for the study of multiple myeloma and plasma cell leukemia
HG Drexler et al.
LEUKEMIA RESEARCH (2000)
分享论文
